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The first 100 kidney transplants from living related
donors at Groote Schuur Hospital
D. KAHN, A. R. PONTIN, R. PIKE, J. E. JACOBSON
Abstract hnproved results with cadaver kidney transplanta-
tion and the increase in the number of cadaver
organs have caused the continued use of donor
kidneys from living relatives to be questioned. In
this analysis of our first 100 renal transplants
involving a living related donor, the 5-year graft
survival rate was 70%. The 5-year graft survival
rate for recipients of grafts from HLA-identical
donors was 81%, as opposed to the 64% survival
rate for grafts from one-haplotype donors.
Recipients of grafts from one-haplotype-matched
donors who received donor-specific blood trans-
fusions demonstrated better graft survival than
those who were not transfused. This analysis
demonstrates that the results of living related kid-
ney transplantation are good, and suggests that
donor-specific blood transfusions may be benefi-
cial.
5 Air Med J 1994; 84: 138-141.
~
e shortage of cadaver donor kidneys and the
superior patient and graft survival rates in cases
where the donor was a living relative were in the
past the major reasons for using organs from living
related donors for kidney transplantation in patients
with end-stage renal failure. I-3 Since the introduction of
the immunosuppressive agent cyclosporin, the results of
kidney transplantation with grafts from cadaver donors
have improved significantly and the difference in graft
survival rate compared with transplants from Eving
related donors is not as great"" Furthermore, with the
increased acceptance of the concept of clinical brain
death and the increased public awareness of organ
donation, the shortage of cadaver organs is not as criti-
cal as it was before. Added to these considerations is the
risk, although minor, to the well-being of a perfectly
healthy donor.6-9 In the light of the above, the continued
use of organs from living related donors for transplanta-
tion has been questioned. In this study we reviewed the
results of kidney transplantation from living related
donors at our institution.
Methods
Recipient selection criteria
Standard criteria were used for the selection of patients
with end-stage renal failure for dialysis and transplanta-
tion; these took into account the aetiology of the renal
disease, the results of an extensive clinical evaluation to
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determine the general health of the patient and the pre-
sence of any complications of renal failure. A detailed
social history was included in the patient evaluation to
assess the feasibility of a transplant from a living related
donor.
Selection of the donor
All potential living related donors were first screened in
respect of ABO compatibility, a leucocyte crossmatch,
and emotional stability and motivation. Potential donors
remaining after the initial screening process were investi-
gated to confirm excellent general health and bilateral
renal function. Tests were directed towards detection of
unsuspected extrarenal pathology. The quality of. renal
function' and the possibility of any anatomical abnormal-
ities in the kidneys were also investigated. The [mal
selection of the donor, if several medically suitable rela-
tives were available, was made on the basis of histo-
compatibility testing; an HlA-identical sibling was the
ideal choice. Angiographic evaluation of the selected
donor was undertaken to determine the exact status Qf
the renal arteries and to rule out the possibility of any
unsuspected intrarenal lesions. When either kidney was
demonstrated satisfactory for use, the left was usually
chosen since the longer renal vein contributed to the




Conventional surgical techniques were used for the
donor nephrectomy and subsequent transplant. 10,11 The
donor received 1 litre of normal saline overnight to
ensure adequate hydration and 200 ml of 20% mannitol
at the time of induction of general anaesthesia to main-
tain a diuresis. Under general anaesthesia and with the
patient in the full kidney position, a loin incision either
between the 11th and 12th ribs or over the 12th rib was
made. The kidney was mobilised by means of an extra-
peritoneal approach. When the left kidney was selected,
the adrenal and gonadal veins were ligated and divided,
and adequate lengths of the renal artery and vein and
the ureter mobilised. The ureter was clamped and divid-
ed as distally as possible, the renal artery clamped and
divided flush with the aona and the renal vein clamped
and divided proximal to the adrenal vein. When the
right kidney was used the renal vein was divided with a
patch of vena cava and the renal artery clamped and
divided as proximally as possible. The kidneys were
immediately flushed with and preserved with Euro-
Collins solution. Haemostasis was secured, the wound
closed in layers and a corrugated drain left in silu.
Recipient operation
The transplant procedure was performed through an
incision in the right or left iliac fossa and an extra-peri-
toneal approach used to mobilise the iliac vessels. The
donor renal vein was anastomosed end-to-side to the
recipient external iliac vein and the donor renal artery
anastomosed end-to-end to the recipient internal iliac
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FIG. 2.
Overall cumulative patient and graft survival rates in
recipients of transplants from living relatives.
Of the 100 living related transplants, 48 transplants
involved grafts from HLA-identical siblings. The
remaining 52 transplants were grafts from one-haplo-
type-matched, related donors. On 82 occasions the
transplant involved a sibling and the remaining 18 grafts
were from a parent to a child.
Donor-specific blood transfusions were introduced in
our unit in May 1982 and were used until August 1987.
Thirty-three patients who had a one-haplotype match
with the donor received donor-specific transfusions.
The cumulative patient and graft survival of the first
100 transplants involving a living related donor are
shown in Fig. 2. The cumulative patient survival rates at
1 and 5 years were 90% and 74% respectively. The
cumulative probabilities of the graft surviving 1 and 5
years were 86% and 70% respectively.
Results
Inununosuppression protocol
In the early pan of the study patients were treated with
azathioprine and steroids. Cyclosporin was introduced
at our ~stitution in 1983 and the immunosuppression
regimen consisted of cyclosporin and steroids. A 'triple
therapy' immunosuppression protocol consisting of
steroids, cyclosporin and azathioprine has been used in
our unit since 1987. Intravenous cyclosporin 2 mg/kg
was given intra-operatively. The oral cyclosporin was
commenced the following day at a dose of 10 mg/kg/day
in two divided doses. Whole-blood cyclosporin trough
levels were maintained at about 500 nglml. Azathioprine
1 - 2 mglkg was given intra-operatively and 2 - 3 mglkg
daily postoperatively. Solu-Medrol 500 mg was given
intra-operatively and oral methylprednisolone (Memol;
Upjohn) was given at a dose of 24 mg per day. Cyclo-
sporin was stopped at either 3 or 6 months and the
patients maintained on methylprednisolone and azathio-
prine.
Rejection episodes were initially treated with bolus
intravenous doses of steroids. Rejection episodes resis-
tant to steroid therapy were treated in the early pan of
the study with anti-Iymphocyte globulin (ALG). Since
1987 steroid-resistant rejection episodes have been
treated with the mouse monoclonal antibody, OKT3.
Donor-specific blood transfusions
Between May 1982 and August 1987 patients who were
one-haplotype-matched with the donor were treated
with donor-specific blood transfusions. The patients
\vere transfused on three occasions with 200 ml blood
from the donor at 2-weekly intervals and were given aza-
thioprine at the time of the transfusion. The transplant
procedure was scheduled for a convenient time at least 2
weeks after the last transfusion. A leucocyte crossmatch
was performed before each transfusion and before the
transplant procedure.
Seven hundred and sixty-six kidney transplants were
performed at Groote Schuur Hospital between
December 1970 and August 1988. One hundred of the
766 transplants involved living related donors; the inci-
dence of living related transplants at our institution was
13%. Of the 100 patients who received an allograft from
a living related donor, 64 were male and 36 female, and
the mean age was 29,96 years (range 9 - 52 years).
The total annual number of kidney transplants per-
formed in our unit has increased over the years (Fig. 1)
and the proportion of transplants involving living related
donors has ranged between 10% and 20%. The number
of living related transplants has increased in recent
years; two-thirds were performed within the last 6 years.
The survival of grafts in patients who were HLA-
identical and those who had a one-haplotype match with
the donor are shown in Fig. 3. The p~tients who were
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FIG. 1.
Total number of kidney transplants and the number of
kidney transplants from living relatives each year.
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FIG. 3.
Cumulative graft survival in recipients of HLA-identical




Effect of donor-specific blood transfusions on the sur-
vival of one-haplotype-matched kidney grafts from living
related donors.
FIG. 5.
Cumulative graft survival rates in recipients of HLA-
identical grafts and recipients of one-haplotype-matched
grafts who received donor-specific blood transfusions.
As can be seen from Fig. 5, there was no difference
in the graft survival rates of the patients who were HLA-
identical with the donor and the patients who were one-
haplotype-matched with the donor and who received
donor-specific blood transfusions.
Discussion
In the early days of renal transplantation, when chronic
haemodialysis was in its infancy and not readily available
to all patients, the diagnosis of end-stage renal failure
was virtually a death sentence for the majority of
patients. A successful renal transplant appeared the only
means of saving these patients but unfortunately, not
only were cadaver donor organs in short supply, but
the results of such transplants were very poor. Trans-
plantation from a living related donor was therefore fre-
quently the only hope for recipient survivaL!'
However, the situation has changed in recent years.
With refinements in surgical technique and peri-opera-
tive management, the introduction of new immunosup-
pressive regimens, particularly the use of cyclosporin""
and improvements in organ preservation, the results of
cadaveric renal transplantation have improved signifi-
cantly."'!' Furthermore, chronic haemodialysis and peri-
toneal dialysis have also improved and become more
readily available, while the shortage of cadaver donors,
although still a problem, is not as critical. The contin-
ued use .of living related donors for transplantation has
therefore been questioned. This report analyses the
results of the first 100 kidney transplants from living
related donors at Groote Schuur Hospital.
This analysis confirms the good results that can be
achieved with kidney transplantation involving living
related donors. As expected, the outcome in the patients
who were HLA-identical with the donor was bener than
in the patients who only had a one-haplotype match
with the donor. The results after renal transplantation in
the one-haplotype-matched patients before the use of
donor-specific transfusions were extremely poor. It was
because of these initial bad results that we abandoned
using one-haplotype-matched living related donors. The
reports of the favourable effects of donor-specific trans-
fusions in transplantation led to the re-introduction of
one-haplotype-matched transplants from living related
donors at our institution.!,,16 In this study the graft sur-
vival rate in the patients who had a one-haplotype match
with the donor and who received donor-specific transfu-
sions was bener than in the patients who did not receive
transfusions and as good as in the patients who were
HLA-identical with the donor. Unfortunately the true
impact of donor-specific transfusions in the recipients
who had a one-haplotype match \vith the donor cannot
be accurately assessed because cyclosporin was intro-
duced at about the same time. This potent immuno-
suppressive agent may account for the improved results
in the one-haplotype-matched patients who received
donor-specific transfusions.
The debate about the use of living related donors
remains unresolved, One of the most compelling argu-
ments against kidney donation from living relatives is
that it is not completely safe for the donor. Nephrec-
tomy in the living related donor is a major surgical pro-
cedure and the postoperative complication rate has been
estimated to be between 15% and 47%.6,17-20 Most of the
complications are, however, minor. Major complica-
tions are reported to occur in fewer than 3% of living
related donors. 17-2o A death in such a donor is a cata-
strophe." However, the overall mortality rate among liv-
ing related donors is reported to be less than 0,1 %.6-9 In
this study there was no mortality and complications
were mostly minor.
Furthermore, long-term follow-up studies of living
kidney donors have given conflicting results with regard
to the prevalence of hypertension'! and the amount of
urinary protein excretion."-23 However, the renal func-
tion does not deteriorate after donation at a rate more
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graft survival than the patients who only had a one-hap-
lotype match with the donor (P < 0,05). The cumula-
tive graft survival rates at I and 5 years in the patients
who were HLA-identical with the donor were 95% and
81 % respectively. In patients who had a one-haplotype
match with the donor, the 1- and 5-year graft survival
rates were 79% and 64% respectively.
The effect of donor-specific blood transfusions on
graft survival in patients who were matched for only one
haplotype with the donor is shown in Fig. 4. The cumu-
lative graft survival rates at I year and 5 years were 97%
and 81 % respectively in patients who received donor-
specific transfusions, and 51 % and 36% respectively in












The use of living related kidney donors has several
advantages over cadaver donors. Most important is the
superior graft and patient survival rate following renal
transplantation from such donors. The use of cyclo-
sporin has, however, narrowed the gap in the graft sur-
vival rate between living related and cadaver renal trans-
plantation. Grafts from living related donors still have a
10 - 15% advantage in survival at I year!"
The shortage of cadaver donor kidneys is another
reason in favour of organs from living related donors.
Some patients on dialysis have to wait a long time before
a cadaver kidney can be found. During this time they
risk needing a blood transfusion and possible sensitisa-.
tion. The shortage of cadaver donor organs is related ill
part to a problem of physician awareness - many donor
organs are lost because physicians looking after potential
donors do not know about organ donation or are reluc-
tant to refer donors to transplant centres. 27 At present
only a small proportion of potential cadaver donors are
referred. An increase in the number of cadaver donor
referrals would provide more than enough kidneys for
patients on dialysis who could benefit from a transplant.
The shortage of organs for transplantation would thus
best be resolved by an increase in physician and public
awareness about organ donation and transplantation
rather than the use of living related donors. In our unit,
as a result of several awareness programmes, the num-
ber of donor referrals, especially from smaller peripheral
hospitals, continues to increase.
In summary, this analysis confirms the good results
obtained with transplants from living relatives and sug-
gests that donor-specific blood transfusions in patients
with a one-haplotype match \vith the donor are benefi-
cial. However, the continued use of living related donors
could be avoided if there were not a shortage of cadaver
kidneys. The shortage of cadaver organs for transplanta-
tion can be improved by education of physicians and the
public about organ donation. In addition the results of
cadaver renal transplantation may improve further with
the introduction of new immunosuppressive agents and
protocols.
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